Blood Transfusion Requirements for Patients with Pyruvate Kinase Deficiency

Rationale for Irradiation of Blood Components

• The American Association of Blood Banks (AABB) guidelines specifically identify that patients with certain hematological conditions, including pyruvate kinase deficiency, require irradiated blood to prevent transfusion-associated graft-versus-host disease (TA-GVHD) 1
• Patients with pyruvate kinase deficiency (PKD) fall into the category of patients requiring irradiated blood components due to their hematological condition 1

Specific Blood Treatment Requirements

• Only cellular components require irradiation, including whole blood, red blood cells, platelets, and granulocytes 1, 2

Timing Considerations for Blood Testing and Transfusion

• Blood testing for PK enzyme activity should be delayed as long as possible after previous transfusions, ideally at least 50 days after the last transfusion to minimize the effect of donor red blood cells on enzyme activity measurements 2
• In transfusion-dependent patients, this waiting period may not be possible, and results should be interpreted with caution 2

Transfusion Approach in PKD

• Patients with PKD may tolerate anemia better than expected due to increased red cell 2,3-DPG content, which causes a rightward shift in the oxygen dissociation curve 3

Special Considerations

• Patients with PKD may develop iron overload even when transfusion-independent, likely due to ineffective erythropoiesis and inappropriately low hepcidin levels 3, 4
• Donor contamination can lead to falsely normal PK enzyme activity levels, and the contribution of normal donor red cells can mask the enzyme deficiency for up to 120 days after transfusion 2

Practical Management Points

• Check patient details against those on the blood bag before administration, and irradiated blood components should be used within their specific storage and expiry times to avoid wastage 1